Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283478 · ClinicalTrials.gov registry record · NA
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
A NA study, sponsored by Kentuckiana Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00283478 is a NA study that has completed, run by Kentuckiana Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT00283478, a NA study, has completed, sponsored by Kentuckiana Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
Interventions
- DRUG Gemcitabine
- DRUG Iscar Quercus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283478
The ClinicalTrials.gov registry entry for NCT00283478 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kentuckiana Cancer Institute, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00283478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283478 about?
NCT00283478 is a clinical study titled "Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer". To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
What is the current status of trial NCT00283478?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2004-05. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00283478?
The interventions under investigation include: Gemcitabine (DRUG), Iscar Quercus (DRUG).
Who is sponsoring clinical trial NCT00283478?
This trial is sponsored by Kentuckiana Cancer Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.